Luye Pharma Group Ltd.

As of December 31, 2025, Luye Pharma Group Ltd. carries a market capitalization of 10.94B, placing it among publicly traded companies globally. Its enterprise value stands at 15.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Luye Pharma Group Ltd.'s next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2025, Luye Pharma Group Ltd. has 3.99B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Luye Pharma Group Ltd. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Luye Pharma Group Ltd.'s stock has declined approximately 50.78% over the past 52 weeks. The 50-day moving average sits at 1.88, while the 200-day moving average is 2.29.

As of December 31, 2025, Luye Pharma Group Ltd. holds 8.34B in cash and equivalents against 10.48B in total debt, resulting in a net debt position of 5.40B. Total book value stands at 17.89B, with working capital of 5.89B providing operational flexibility.